<\/a>Abdominal Imaging<\/h2>\n<\/div>\n<\/div>\n\n\n![\"Ersan](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/AI_AltunErsan_Web_220923-150x150.jpg\")
<\/div>\n\nMultiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer<\/h3>\n
Purpose: The purpose of this research study is to test if a new MRI imaging exam called mpMRI combined with PIRADSv2 is useful for evaluating prostate cancer in finding aggressive diseases.
\nPI: Ersan Altun, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n\n\n<\/a>Breast Imaging<\/h2>\n<\/div>\n<\/div>\n\n\n![\"Cherie](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/BI_KuzmiakCherie_web-150x150.jpg\")
<\/div>\n\nReproductive Axis Maturation in the Early Post- Menarchal Years: a Pilot Study<\/h3>\n
The purpose of this study is to determine the physiologic and pathophysiologic
\nunderpinnings of irregular menstrual cycles among adolescents in the early postmenarchal
\nperiod.
\nPI: Cherie Kuzmiak, DO
\nActive Enrolling
\nFor more information: Clinicaltrials.gov<\/a><\/div>\n<\/div>\n
\n\n\n<\/div>\n\nTMIST<\/h3>\n
Purpose: To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of “advanced” breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of clinical follow-up after the last screen (T4).
\nParticipants: Women being screened for breast cancer.
\nPI: Cherie Kuzmiak, DO
\nActive – Closed to Enrollment
\nFor more information check out clinicaltrials.gov<\/a><\/div>\n<\/div>\n\n\n<\/a>Interventional Radiology<\/h2>\n<\/div>\n<\/div>\n\n\n![\"Nikki](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/VIR_KeefeNikki_web_250702-150x150.jpg\")
<\/p>\n<\/div>\n
\nLocal Radiofrequency Ablation plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors<\/h3>\n
Purpose: To determine if the combination of kyphoplasty with Osteocool ablation plus radiation therapy results in improved patient pain management for the treatment of thoracic and lumbar spine tumors.
\nPI: Nicole Keefe, MD
\nActive Enrolling<\/div>\n<\/div>\n
\n\n\n![\"Nima](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/VIR_KokabiNima_Web_230401-150x150.jpg\")
<\/p>\n<\/div>\n
\nObservational basket trial to collect tissue to develop and train a live tumor diagnostic platform (ELEPHAS-02)<\/h3>\n
The primary objective of this study is to train and validate the ELEPHAS live tumor diagnostic platform and determine the ex-vivo accuracy of the Cybrid Score using in-vivo RECIST 1.1 as the reference method.
\nParticipants: We will enroll up to 416 subjects across all study sites. Subjects suspected of or diagnosed with Stage IV\/metastatic and undergoing biopsy for the following:(1) Lung: Non-small cell lung cancer (NSCLC), (2) Head and Neck: Squamous Cell Carcinoma, (HNSCC), excluding nasopharyngeal and salivary gland cancers, (3) Kidney: Clear Cell Renal Cell Carcinoma (ccRCC), (4) Bladder: Urothelial Carcinoma (UC), (5) Skin: Cutaneous Melanoma, excluding Uveal Melanoma, (6)Uterus: endometrial cancer, (7) Colon and Rectum: Microsatellite instability-high (MSIH)\/ deficient mismatch repair (dMMR) Colorectal Cancer (CRC) (8)Liver: Hepatocellular Carcinoma.
\nPI: Nima Kokabi, MD, FRCPC
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n<\/p>\n<\/div>\n
\nA Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice (OCCLUDE)<\/h3>\n
Purpose: To assess effectiveness and safety outcomes of patients who undergo embolization with Obsidio\u2122 Conformable Embolic.
\nPI: Nima Kokabi, MD, FRCPC
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n<\/p>\n<\/div>\n
\nEvaluation of a Simple-Prep Controlled Embolic (GPX Trial)<\/h3>\n
Purpose: To evaluate the safety and effectiveness of the GPX\u00ae Embolic Device when used as indicated for embolization requiring distal vessel penetration.
\nPI: Nima Kokabi, MD, FRCPC
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n![\"David](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/VIR_MauroDavid_Web_220923-150x150.jpg\")
<\/p>\n<\/div>\n
\nA prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres\u00ae Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in hepatocellular carcinoma (HCC) patients (DOORwaY90 Study)<\/h3>\n
Purpose: To evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.
\nPI: David Mauro, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n<\/p>\n<\/div>\n
\nEfficacy & Safety of LOBOTM Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations (PAVM)<\/h3>\n
Purpose:To evaluate both the technical success and efficacy of PAVM embolization using the LOBO\u2122 device.
\nPI: David Mauro, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n![\"Gloria](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/VIR_SalazarGloria_Web_220706-150x150.jpg\")
<\/p>\n<\/div>\n
\nRandomized Controlled, Single-blind, Parallel-Group Trial of Ovarian Vein and Pelvic Vein Embolization in Women with Chronic Pelvic Pain and Pelvic Varices (EMBOLIZE Trial)<\/h3>\n
Purpose: To assess whether bilateral ovarian vein embolization (OVE) and pelvic vein embolization (PVE) reduces pain symptoms and improves quality of life in women with pelvic venous disease (PeVD) and chronic pelvic pain (CPP).
\nPI: Gloria Salazar, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n![\"Hyeon](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/VIR_YuHyeon_Web_220923-150x150.jpg\")
<\/p>\n<\/div>\n
\nStreamlined Resin Y90 Radiation Segmentectomy for Small HCC: One & Done Trial<\/h3>\n
Purpose: To evaluate the safety and efficacy of streamlining Yttrium-90 radioembolization workflow for patients with small Hepatocellular Carcinoma (HCC) ( < 5 cm) that have no aggressive features on baseline imaging.
\nPI: Hyeon yu, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n\n\n<\/a>Molecular Imaging & Therapeutics<\/h2>\n<\/div>\n<\/div>\n\n\n![\"Jorge](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/MIT_OldanJorge_Web_220614-150x150.jpg\")
<\/div>\n\nEvaluation of Endometriosis with 18F-fluoroestradiol PET \/ MRI<\/h3>\n
The primary objective is to evaluate the sensitivity and specificity of 18F-fluorofuranylnorprogesterone (FFNP) PET\/MR for evaluating endometriosis. Secondary objectives include comparing PET to conventional MRI, using histopathology from laparotomy as the gold standard and evaluating association of uptake values (SUV-max) with EHP-30 and pain rating scales, controlling for covariates.
\nPI: Jorge Oldan, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n<\/div>\n\nA Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer<\/h3>\n
Purpose: to assess the accuracy of FFNP-PET in predicting response to abemaciclib + endocrine therapy.
\nPI: Jorge Oldan, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n\n\n<\/div>\n\nPortable Gamma Camera for Evaluation of Therapeutic Radiopharmaceutical Extravasation<\/h3>\n
Purpose: to use a portable gamma camera to determine the extravasation rates in patients receiving Radiopharmaceutical therapy.
\nPI: Jorge Oldan, MD
\nActive Enrolling<\/div>\n<\/div>\n
\n\n\n<\/div>\n\nP01 Endometriosis Diagnostic and Therapeutic Collaborative Center- Project 1: Diagnosis and Treatment of Endometriosis: A Translational Approach<\/h3>\n
Purpose:To determine mechanisms preventing inflammation resolution in women with endometriosis.
\nPI: Jorge Oldan, MD
\nActive – Closed to Enrollment<\/div>\n<\/div>\n
\n\n\n<\/div>\n\nEA1211: Interim FDG-PET\/CT for PreDIcting Response of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial<\/h3>\n
Purpose: To investigate the performance of FDG-PET\/CT as a predictor of pathologic complete respone (pCR) in patients treated with neoadjuvant HER2-directed therapy.
\nPI: Jorge Oldan, MD
\nActive – Closed to Enrollment<\/p>\n
For more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n\n\n<\/a>Neuroradiology<\/h2>\n<\/div>\n<\/div>\n\n\n![\"Yueh](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/NEURO_LeeYueh_Web_0321-e1722004744795-150x150.jpg\")
<\/div>\n\nHigh Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging<\/h3>\n
Purpose: This is a 3 arm single-center study of 35 patients scheduled to undergo a breast or thyroid biopsy that consent to undergo an acoustic angiography in conjunction with b-mode ultrasound prior to their scheduled biopsy. Prior to imaging clinical patients, the third arm will include 5 healthy volunteers that will be imaged to optimize imaging parameters. The primary objective of this study is to compare the sensitivity and specificity of super-resolution acoustic angiography with traditional b-mode ultrasound in the distinction of malignant versus benign breast and thyroid lesions. Secondary objectives include a comparison of area under the curve (AUC) for acoustic angiography versus b-mode ultrasound and a comparison of radiologist preference for the two imaging techniques for each of 3 lesion characteristics.
\nPI: Yeah Lee, MD, PhD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n
\n\n\n<\/div>\n\nAcademic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging<\/h3>\n
Purpose:To evaluate the sensitivity and specificity of Contrast Enhanced Super-Resolution (CESR) imaging in the analysis of known breast, liver, and kidney lesions by comparing image analyses to the pathological results for these lesions.
\nPI: Yeah Lee, MD, PhD
\nActive – Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n
\n\n\n<\/div>\n\nEAF223: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)<\/h3>\n
Purpose:For each biomarker (Dynamic Susceptibility Contrast-Enhanced MR Imaging, 18F-fluciclovine PET, MR Spectroscopy), to evaluate whether the biomarker can stratify patients with newly diagnosed glioblastoma (GBM) that have progressive enhancement within 12 weeks post-XRT into risk groups based on overall survival.
\nPI: Yeah Lee, MD, PhD
\nActive – Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/a>Pediatrics<\/h2>\n\n\n![\"Will](\"https:\/\/www.med.unc.edu\/radiology\/wp-content\/uploads\/sites\/1384\/2024\/02\/PEDS_PryorWill_Web_220808-150x150.jpg\")
<\/div>\n\nAccuracy of ultrasound for the evaluation of percutaneous gastrostomy tube position and leakage<\/h3>\n
Evaluate the accuracy of ultrasound for the evaluation of percutaneous gastrostomy tube positioning following replacement in comparison with fluoroscopic evaluation.
\nPI: William Pryor, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n
<\/div>\nMultiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer<\/h3>\n
Purpose: The purpose of this research study is to test if a new MRI imaging exam called mpMRI combined with PIRADSv2 is useful for evaluating prostate cancer in finding aggressive diseases. The purpose of this study is to determine the physiologic and pathophysiologic Purpose: To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of “advanced” breast cancer at any time during a period of 4.5 years from randomization, including the period of active screening and a period of clinical follow-up after the last screen (T4). Purpose: To determine if the combination of kyphoplasty with Osteocool ablation plus radiation therapy results in improved patient pain management for the treatment of thoracic and lumbar spine tumors. The primary objective of this study is to train and validate the ELEPHAS live tumor diagnostic platform and determine the ex-vivo accuracy of the Cybrid Score using in-vivo RECIST 1.1 as the reference method. Purpose: To assess effectiveness and safety outcomes of patients who undergo embolization with Obsidio\u2122 Conformable Embolic. Purpose: To evaluate the safety and effectiveness of the GPX\u00ae Embolic Device when used as indicated for embolization requiring distal vessel penetration. Purpose: To evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C. Purpose:To evaluate both the technical success and efficacy of PAVM embolization using the LOBO\u2122 device. Purpose: To assess whether bilateral ovarian vein embolization (OVE) and pelvic vein embolization (PVE) reduces pain symptoms and improves quality of life in women with pelvic venous disease (PeVD) and chronic pelvic pain (CPP). Purpose: To evaluate the safety and efficacy of streamlining Yttrium-90 radioembolization workflow for patients with small Hepatocellular Carcinoma (HCC) ( < 5 cm) that have no aggressive features on baseline imaging. The primary objective is to evaluate the sensitivity and specificity of 18F-fluorofuranylnorprogesterone (FFNP) PET\/MR for evaluating endometriosis. Secondary objectives include comparing PET to conventional MRI, using histopathology from laparotomy as the gold standard and evaluating association of uptake values (SUV-max) with EHP-30 and pain rating scales, controlling for covariates. Purpose: to assess the accuracy of FFNP-PET in predicting response to abemaciclib + endocrine therapy. Purpose: to use a portable gamma camera to determine the extravasation rates in patients receiving Radiopharmaceutical therapy. Purpose:To determine mechanisms preventing inflammation resolution in women with endometriosis. Purpose: To investigate the performance of FDG-PET\/CT as a predictor of pathologic complete respone (pCR) in patients treated with neoadjuvant HER2-directed therapy. For more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n Purpose: This is a 3 arm single-center study of 35 patients scheduled to undergo a breast or thyroid biopsy that consent to undergo an acoustic angiography in conjunction with b-mode ultrasound prior to their scheduled biopsy. Prior to imaging clinical patients, the third arm will include 5 healthy volunteers that will be imaged to optimize imaging parameters. The primary objective of this study is to compare the sensitivity and specificity of super-resolution acoustic angiography with traditional b-mode ultrasound in the distinction of malignant versus benign breast and thyroid lesions. Secondary objectives include a comparison of area under the curve (AUC) for acoustic angiography versus b-mode ultrasound and a comparison of radiologist preference for the two imaging techniques for each of 3 lesion characteristics. Purpose:To evaluate the sensitivity and specificity of Contrast Enhanced Super-Resolution (CESR) imaging in the analysis of known breast, liver, and kidney lesions by comparing image analyses to the pathological results for these lesions. Purpose:For each biomarker (Dynamic Susceptibility Contrast-Enhanced MR Imaging, 18F-fluciclovine PET, MR Spectroscopy), to evaluate whether the biomarker can stratify patients with newly diagnosed glioblastoma (GBM) that have progressive enhancement within 12 weeks post-XRT into risk groups based on overall survival. Evaluate the accuracy of ultrasound for the evaluation of percutaneous gastrostomy tube positioning following replacement in comparison with fluoroscopic evaluation.
\nPI: Ersan Altun, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n<\/a>Breast Imaging<\/h2>\n<\/div>\n<\/div>\n
<\/div>\nReproductive Axis Maturation in the Early Post- Menarchal Years: a Pilot Study<\/h3>\n
\nunderpinnings of irregular menstrual cycles among adolescents in the early postmenarchal
\nperiod.
\nPI: Cherie Kuzmiak, DO
\nActive Enrolling
\nFor more information: Clinicaltrials.gov<\/a><\/div>\n<\/div>\n
\n<\/div>\nTMIST<\/h3>\n
\nParticipants: Women being screened for breast cancer.
\nPI: Cherie Kuzmiak, DO
\nActive – Closed to Enrollment
\nFor more information check out clinicaltrials.gov<\/a><\/div>\n<\/div>\n<\/a>Interventional Radiology<\/h2>\n<\/div>\n<\/div>\n
<\/p>\n<\/div>\nLocal Radiofrequency Ablation plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors<\/h3>\n
\nPI: Nicole Keefe, MD
\nActive Enrolling<\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nObservational basket trial to collect tissue to develop and train a live tumor diagnostic platform (ELEPHAS-02)<\/h3>\n
\nParticipants: We will enroll up to 416 subjects across all study sites. Subjects suspected of or diagnosed with Stage IV\/metastatic and undergoing biopsy for the following:(1) Lung: Non-small cell lung cancer (NSCLC), (2) Head and Neck: Squamous Cell Carcinoma, (HNSCC), excluding nasopharyngeal and salivary gland cancers, (3) Kidney: Clear Cell Renal Cell Carcinoma (ccRCC), (4) Bladder: Urothelial Carcinoma (UC), (5) Skin: Cutaneous Melanoma, excluding Uveal Melanoma, (6)Uterus: endometrial cancer, (7) Colon and Rectum: Microsatellite instability-high (MSIH)\/ deficient mismatch repair (dMMR) Colorectal Cancer (CRC) (8)Liver: Hepatocellular Carcinoma.
\nPI: Nima Kokabi, MD, FRCPC
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nA Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice (OCCLUDE)<\/h3>\n
\nPI: Nima Kokabi, MD, FRCPC
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nEvaluation of a Simple-Prep Controlled Embolic (GPX Trial)<\/h3>\n
\nPI: Nima Kokabi, MD, FRCPC
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nA prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres\u00ae Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in hepatocellular carcinoma (HCC) patients (DOORwaY90 Study)<\/h3>\n
\nPI: David Mauro, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nEfficacy & Safety of LOBOTM Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations (PAVM)<\/h3>\n
\nPI: David Mauro, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nRandomized Controlled, Single-blind, Parallel-Group Trial of Ovarian Vein and Pelvic Vein Embolization in Women with Chronic Pelvic Pain and Pelvic Varices (EMBOLIZE Trial)<\/h3>\n
\nPI: Gloria Salazar, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/p>\n<\/div>\nStreamlined Resin Y90 Radiation Segmentectomy for Small HCC: One & Done Trial<\/h3>\n
\nPI: Hyeon yu, MD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n<\/a>Molecular Imaging & Therapeutics<\/h2>\n<\/div>\n<\/div>\n
<\/div>\nEvaluation of Endometriosis with 18F-fluoroestradiol PET \/ MRI<\/h3>\n
\nPI: Jorge Oldan, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/div>\nA Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer<\/h3>\n
\nPI: Jorge Oldan, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.org<\/a><\/div>\n<\/div>\n
\n<\/div>\nPortable Gamma Camera for Evaluation of Therapeutic Radiopharmaceutical Extravasation<\/h3>\n
\nPI: Jorge Oldan, MD
\nActive Enrolling<\/div>\n<\/div>\n
\n<\/div>\nP01 Endometriosis Diagnostic and Therapeutic Collaborative Center- Project 1: Diagnosis and Treatment of Endometriosis: A Translational Approach<\/h3>\n
\nPI: Jorge Oldan, MD
\nActive – Closed to Enrollment<\/div>\n<\/div>\n
\n<\/div>\nEA1211: Interim FDG-PET\/CT for PreDIcting Response of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial<\/h3>\n
\nPI: Jorge Oldan, MD
\nActive – Closed to Enrollment<\/p>\n<\/a>Neuroradiology<\/h2>\n<\/div>\n<\/div>\n
<\/div>\nHigh Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging<\/h3>\n
\nPI: Yeah Lee, MD, PhD
\nActive – Closed to Enrollment
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n
\n<\/div>\nAcademic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging<\/h3>\n
\nPI: Yeah Lee, MD, PhD
\nActive – Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n
\n<\/div>\nEAF223: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)<\/h3>\n
\nPI: Yeah Lee, MD, PhD
\nActive – Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n<\/a>Pediatrics<\/h2>\n
<\/div>\nAccuracy of ultrasound for the evaluation of percutaneous gastrostomy tube position and leakage<\/h3>\n
\nPI: William Pryor, MD
\nActive Enrolling
\nFor more information: ClinicalTrials.gov<\/a><\/div>\n<\/div>\n